Comparative methods for determining MoCA, MMSE, and CDR cut-offs in Alzheimer's disease: insights from the ADNI study [0.03%]
阿尔茨海默病的MoCA、MMSE和CDR临界值测定的比较方法：来自ADNI研究的启示
Samir Atiya,Briseis Aschebrook-Kilfoy,Sreenivas Konda;Alzheimer&#x;s Disease Neuroimaging Initiative
Samir Atiya
Introduction: Accurate cut-off values for the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and Clinical Dementia Rating (CDR) are essential for detecting and staging Alzheimer's disease-rela...
Blood-based biomarkers for Alzheimer's disease in primary care: A French qualitative study exploring perspectives of general practitioners [0.03%]
法国初级保健中阿尔茨海默病的血液生物标志物：探索全科医生的观点定性研究
Antoine Perrin,Laurent Letrilliart,Thomas Gilbert et al.
Antoine Perrin et al.
Correction to "P-tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study" [0.03%]
对“P-tau217 检测对认知障碍患者预设管理的影像：一项随机临床实用性研究”的修正通知
[This corrects the article DOI: 10.1002/dad2.70201.]. © 2026 The Author(s). Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published...
Comparison of three plasma p-tau217 assays to detect PET-confirmed Alzheimer's pathologies [0.03%]
三种血浆p-tau217检测方法与PET确认的阿尔茨海默病病理改变的相关性比较研究
Sayo Matsuura,Kenji Tagai,Harutsugu Tatebe et al.
Sayo Matsuura et al.
Introduction: Plasma phosphorylated tau 217 (p-tau217) has emerged as a promising blood-based biomarker for Alzheimer's disease (AD) diagnosis, but cross-platform comparability remains unclear. We evaluated three platform...
The vicious cycle of stigma: A multi-level analysis of dementia help seeking and care in Malaysia [0.03%]
恶性循环：马来西亚痴呆症求医和照护的多层分析
Jennifer N W Lim,Nurul Syasya Mohd Ridzwan Goh,Chia Zhen Tan et al.
Jennifer N W Lim et al.
Background: Dementia stigma impedes timely diagnosis in low- and middle-income countries. This study examines how cultural, social, and structural factors influence stigma in Malaysia's multiethnic context. ...
Accuracy of clinical diagnosis of behavioral variant frontotemporal dementia: A systematic review and meta-analysis [0.03%]
行为变异型额颞叶痴呆临床诊断准确性的系统评价和 meta 分析
Daniele Urso,Stefano Giannoni-Luza,Silvio Ionta et al.
Daniele Urso et al.
Introduction: Accurate diagnosis of behavioral variant frontotemporal dementia (bvFTD) remains difficult due to overlapping symptoms with other conditions. We aimed to evaluate the diagnostic accuracy of bvFTD clinical cr...
Family history, perceived risk, and perceived threat of Alzheimer's disease among Latino residents of northern Manhattan [0.03%]
曼哈顿北部拉丁居民的家庭史、患病风险及阿兹海默症威胁的感知状况
Eleanor J Murphy,John B Wetmore,María Cabán et al.
Eleanor J Murphy et al.
Introduction: The relations of Alzheimer's disease (AD) family history to risk perceptions and disease-related anxiety (AD threat) have been under-investigated in Latino populations. ...
Tears as a window to Alzheimer's disease: A systematic review of biomarkers for early detection [0.03%]
阿尔茨海默病眼泪标志物的系统综述：早期检测的新窗口
Inés López-Cuenca,Rubén Masa-Castro,Yael Hoz-Ruiz et al.
Inés López-Cuenca et al.
Alzheimer's disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid beta and tau proteins, leading to neuronal degeneration and brain atrophy. While cerebrospinal fluid and blood biomarkers have advanced ...
Network-based cortical atrophy predicts longitudinal clinical decline in sporadic behavioral variant frontotemporal dementia [0.03%]
基于网络的皮层萎缩可预测散发性行为变异型额颞叶痴呆的临床纵向下降趋势
Yuta Katsumi,Erin A Krahn,Thiago Paranhos et al.
Yuta Katsumi et al.
Introduction: Behavioral variant frontotemporal dementia (bvFTD) is typically characterized by progressive deficits across several socioemotional and cognitive functions. Clinical prognostication in bvFTD remains a challe...
Plasma p-tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS-HD [0.03%]
血浆p-tau217与认知障碍：在HABS-HD中评估不同种族和族裔群体中的生物标志物公平性
Cellas A Hayes,Zara Najmi,Joey Annette Contreras et al.
Cellas A Hayes et al.
Introduction: Plasma phosphorylated tau 217 (p-tau217) is a leading blood-based biomarker of Alzheimer's disease. Its performance in underrepresented racial/ethnic groups remains insufficiently characterized. ...